CN101830828A - 一种Salen Zn(Ⅱ)配合物及其制备方法和应用 - Google Patents
一种Salen Zn(Ⅱ)配合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN101830828A CN101830828A CN201010132979A CN201010132979A CN101830828A CN 101830828 A CN101830828 A CN 101830828A CN 201010132979 A CN201010132979 A CN 201010132979A CN 201010132979 A CN201010132979 A CN 201010132979A CN 101830828 A CN101830828 A CN 101830828A
- Authority
- CN
- China
- Prior art keywords
- salen
- title complex
- preparation
- phenylene diamine
- coordination compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VEUMANXWQDHAJV-UHFFFAOYSA-N 2-[2-[(2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol Chemical compound OC1=CC=CC=C1C=NCCN=CC1=CC=CC=C1O VEUMANXWQDHAJV-UHFFFAOYSA-N 0.000 title claims abstract description 53
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 title abstract description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 48
- 238000010992 reflux Methods 0.000 claims description 26
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 17
- 238000001816 cooling Methods 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 12
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 8
- 230000004570 RNA-binding Effects 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 150000004985 diamines Chemical class 0.000 claims description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 6
- DPZSNGJNFHWQDC-ARJAWSKDSA-N (z)-2,3-diaminobut-2-enedinitrile Chemical compound N#CC(/N)=C(/N)C#N DPZSNGJNFHWQDC-ARJAWSKDSA-N 0.000 claims description 5
- RAUWPNXIALNKQM-UHFFFAOYSA-N 4-nitro-1,2-phenylenediamine Chemical compound NC1=CC=C([N+]([O-])=O)C=C1N RAUWPNXIALNKQM-UHFFFAOYSA-N 0.000 claims description 5
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 229910052786 argon Inorganic materials 0.000 claims description 4
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 claims description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
- RXCOGDYOZQGGMK-UHFFFAOYSA-N (3,4-diaminophenyl)-phenylmethanone Chemical compound C1=C(N)C(N)=CC=C1C(=O)C1=CC=CC=C1 RXCOGDYOZQGGMK-UHFFFAOYSA-N 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- DGRGLKZMKWPMOH-UHFFFAOYSA-N 4-methylbenzene-1,2-diamine Chemical compound CC1=CC=C(N)C(N)=C1 DGRGLKZMKWPMOH-UHFFFAOYSA-N 0.000 claims description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical group [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 2
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004012 amifampridine Drugs 0.000 claims description 2
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 239000004246 zinc acetate Substances 0.000 claims description 2
- 238000010839 reverse transcription Methods 0.000 abstract description 9
- 241000700605 Viruses Species 0.000 abstract description 8
- 229910052751 metal Inorganic materials 0.000 abstract description 8
- 239000002184 metal Substances 0.000 abstract description 8
- 230000003993 interaction Effects 0.000 abstract description 7
- 229920002477 rna polymer Polymers 0.000 abstract description 7
- 208000032839 leukemia Diseases 0.000 abstract description 5
- 102100034343 Integrase Human genes 0.000 abstract description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000009881 electrostatic interaction Effects 0.000 abstract description 3
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- 230000002209 hydrophobic effect Effects 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000035484 reaction time Effects 0.000 abstract description 2
- 150000001768 cations Chemical group 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 99
- 239000000243 solution Substances 0.000 description 61
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 150000001412 amines Chemical group 0.000 description 23
- 230000002103 transcriptional effect Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 238000005303 weighing Methods 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000001291 vacuum drying Methods 0.000 description 11
- BEAZKUGSCHFXIQ-UHFFFAOYSA-L zinc;diacetate;dihydrate Chemical compound O.O.[Zn+2].CC([O-])=O.CC([O-])=O BEAZKUGSCHFXIQ-UHFFFAOYSA-L 0.000 description 11
- 208000030507 AIDS Diseases 0.000 description 9
- 108020000999 Viral RNA Proteins 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910000474 mercury oxide Inorganic materials 0.000 description 4
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 4
- -1 nucleoside triphosphate derivative Chemical class 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XTBLDMQMUSHDEN-UHFFFAOYSA-N naphthalene-2,3-diamine Chemical compound C1=CC=C2C=C(N)C(N)=CC2=C1 XTBLDMQMUSHDEN-UHFFFAOYSA-N 0.000 description 2
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical group [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
Images
Abstract
本发明公开了一种Salen Zn(Ⅱ)配合物及其制备方法和应用。本发明Salen Zn(Ⅱ)配合物的阳离子部分的结构如通式(I)所示。本发明优化了Salen金属配合物的制备工艺,缩短了反应时间,提高了产率,得到的配合物具有很好的水溶性。本发明Salen Zn(Ⅱ)配合物利用Salen金属配合物轴向配位能力与RNA结构中单链部位碱基中的电子给体形成配位键,与仅靠静电作用。疏水作用、氢键以及π-π堆积等弱相互作用相比,是一种具有更高亲和力的RNA结合试剂,从而更加有效的阻断逆转录酶对病毒RNA的逆转录作用,为治疗由逆转录酶病毒引起的重大疾病(如艾滋病、癌症、白血病等)的药物的开发提供一定的理论基础。
Description
技术领域
本发明涉及RNA结合试剂或RNA逆转录酶抑制剂,具体涉及一种Salen Zn(II)配合物及其制备方法和应用。
背景技术
“逆转录病毒(retrovirus)”是一种携带逆转录酶的病毒。与大部分生物不同,这种病毒并没有DNA,而已RNA作为遗传物质。当这些病毒侵入寄主细胞后,同样能够将遗传信息从单链病毒RNA转录到DNA上去。这一过程与一般转录方向相反,故称“逆转录”,催化此过程的酶被称为“逆转录酶”。在逆转录酶的作用下病毒首先将RNA转变为cDNA,再在DNA复制、转录、翻译等作用下增殖。逆转录酶病毒是RNA病毒,艾滋病和白血病等疾病产生和传播与逆转录酶对病毒RNA的逆转录作用都有直接原因。以逆转录酶为靶点抑制逆转录酶对病毒RNA的逆转录作用,专一性的抑制逆转录酶,可以防止病毒的产生和扩散,降低毒副作用,成为一种消灭肿瘤细胞有效手段,从而对艾滋病、白血病等不易治愈的疾病提供理论依据。
目前临床应用的逆转录酶抑制剂分为两类,即“核苷类逆转录酶抑制剂”和“非核苷类逆转录酶抑制剂”。核苷类逆转录酶抑制剂为核苷类似物,在体内自身能够转化成活性的三磷酸核苷衍生物(类似DNA的底物),与病毒RNA逆转录形成的病毒DNA竞争结合逆转录酶(RT),抑制逆转录酶的作用,从而抑制病毒的复制。尽管这些药物早期用于治疗AIDS及其相关综合征,对治疗HIV阳性/AIDS有一定的效果,可降低死亡率及机会性感染率,但都不能治愈AIDS,而且长期使用会产生严重的抑制骨髓生长的毒副作用和出现明显的抗药性现象,因此面临被淘汰的危险。
通过对大量新化合物的大规模筛选,人们发现有机小分子表现出良好的逆转录酶抑制活性,成为非核苷类逆转录酶抑制剂。它们通过与逆转录酶的相互作用可以引起酶的构型变化,从而降低底物与酶的识别作用。由于这类逆转录酶抑制剂不会直接损坏底物,因此细胞毒性很小。进一步研究这类逆转录酶抑制剂对于未来癌症、艾滋病、白血病等由逆转录酶引起的疾病的治疗具有重要意义。
发明内容
本发明的目的在于根据现有RNA结合试剂及RNA逆转录酶抑制剂中存在的细胞毒性大,副作用强,容易导致抗药性等不足,提供一种水溶性好,活性高,细胞毒性小,不会直接损坏底物,容易吸收的Salen Zn(II)配合物。
本发明另一目的在于提供上述Salen Zn(II)配合物的制备方法。
本发明还有一个目的在于提供Salen Zn(II)配合物的应用。
本发明上述目的通过以下技术方案予以实现:
一种Salen Zn(II)配合物,其阳离子部分的结构如通式(I)所示,
其中,所述乙二胺、环己二胺、二氨基马来腈、苯二胺、2,3-二胺基吡啶、3,4-二胺基吡啶、4-甲氧基邻苯二胺、3,4-二氨基甲苯、4-氟邻苯二胺、4-硝基邻苯二胺、3,4-二氨基二苯甲酮或2,3-二氨基萘,所述阴离子部分为高氯酸根。
本发明Salen Zn(II)配合物的制备方法包括如下步骤:将高氯酸季铵盐(S.S Mandal.U.Varshney.S.Bhattacharya.Bioconjugate.Chem.8(1997),798)与二胺混合,加热回流2h后,向反应液中加入金属盐,继续回流2~3h,停止加热,冷却后析出大量沉淀,经抽滤得到Salen Zn(II)配合物。
其中,所述高氯酸季铵盐、二胺和金属盐的摩尔比为2∶1∶2。
作为一种优选方案,上述制备方法中,所述二胺为乙二胺,环己二胺,二氨基马来腈,苯二胺,2,3-二胺基吡啶,3,4-二胺基吡啶,4-甲氧基邻苯二胺,3,4-二氨基甲苯,4-氟邻苯二胺,4-硝基邻苯二胺,3,4-二氨基二苯甲酮,2,3-二氨基萘。
作为一种优选方案,上述制备方法中,所述金属盐为醋酸锌。
当合成含有2,3-二胺基吡啶或4-甲氧基邻苯二胺的alen Zn(II)配合物时,需要在氩气的保护下进行。
本发明Salen Zn(II)配合物可以用于制备RNA结合试剂或RNA逆转录酶抑制剂。
与现有技术相比,本发明具有如下有益效果:
(1)本发明采用一步法合成金属配合物,优化了反应条件,缩短反应时间,大大提高了产率;
(2)本发明中合成的Salen Zn(II)配合物,具有很好的水溶性;避免引入外来金属,降低产生体内排斥的可能性;具有大的π电子共轭体系,带正电的取代基;
(3)本发明提供的Salen Zn(II)配合物,利用轴向配位能力与RNA结构中单链部位碱基中的电子给体形成配位键,与仅靠静电作用、疏水作用、氢键以及π-π堆积等弱相互作用相比,具有更高亲和力的RNA结合试剂,从而更加有效的阻断逆转录酶对病毒RNA的逆转录作用;
(4)本发明提供的Salen Zn(II)配合物具有作为RNA结合试剂和逆转录酶抑制剂的潜在应用价值,通过紫外光谱滴定研究表明Salen Zn(II)配合物能有效结合RNA;进一步通过凝胶电泳法研究证实该类配合物能有效结合RNA,从而抑制逆转录酶发生作用,是逆转录酶抑制剂。因此本研究中合成的系列金属配合物在作为RNA结合试剂和逆转录酶抑制剂方面具有潜在的应用价值。
附图说明
图1是Salen Zn(II)配合物(通式I)的合成路线图;
图2是不断滴加poly A至配合物6中,配合物电子吸收光谱图;
图3是不断滴加tRNA至配合物6中,配合物电子吸收光谱图;
图4是由凝胶电泳法得到的Salen Zn(II)配合物体外抑制逆转录酶作用的照片;
图5是Salen Zn(II)配合物1-11的阳离子部分的结构图。
具体实施方式
以下结合实施例来进一步解释本发明,但实施例并不对本发明做任何形式的限定。
实施例1
化合物的合成步骤:
(1)高氯酸季胺盐(化合物a)的制备(S.S Mandal.U.Varshney.S.Bhattacharya.Bioconjugate.Chem.8(1997),798);
(2)Salen Zn(II)配合物1的合成:
称取高氯酸季胺盐(化合物a)170mg(0.5mmol)置于50mL圆底烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。向该溶液中加入15mg(0.25mmol)乙二胺,加热回流2h,溶液变成亮黄色。然后加入二水合醋酸锌110mg(0.5mmol)的甲醇溶液,加热回流2h后,停止加热,将溶液放入冰箱冷却,产生淡黄色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到淡黄色粉末固体160mg。产率83%。
元素分析C26H38Cl2N4O12Zn·2H2O理论值:C,40.51;H,5.49;N,7.27.实验值:C,40.34;H,5.71;N,7.03%.1H-NMR(ppm,DMSO--d6):8.91(s,2H),7.82(m,2H),7.33(m,4H),6.24(m,4H),4.47(s,4H),3.79(t,4H),3.19(s,18H).
实施例2
(1)同实施例1;
(2)Salen Zn(II)配合物2的合成:
称取高氯酸季胺盐170mg(0.5mmol)置于50mL圆底烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。向该溶液中加入27mg(0.25mmol)二氨基马来腈,加热回流2h,溶液变成红棕色。然后加入二水合醋酸锌110mg(0.5mmol)的甲醇溶液,加热回流3h后停止加热,将溶液放入冰箱冷却,得到红色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到红色粉末固体85mg。产率42%。
元素分析C28H34Cl2N6O12Zn·2H2O理论值:C,41.06;H,4.68;N,10.26.实验值:C,40.87;H,4.82;N,9.98%.1H-NMR(ppm,DMSO--d6):8.49(s,2H),7.45(d,2H),6.31(m,4H),4.51(s,4H),3.80(t,4H),3.19(s,18H).
实施例3
(1)同实施例1;
(2)Salen Zn(II)配合物3的合成:
称取高氯酸季胺盐170mg(0.5mmol)置于50mL圆底烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。向该溶液中加入27mg(0.25mmol)邻苯二胺,加热回流2h,溶液变成黄色。然后加入二水合醋酸锌110mg(0.5mmol)的甲醇溶液,加热回流3h后停止加热,将溶液放入冰箱冷却,得到黄色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到黄色粉末固体137mg。产率67%。
元素分析C30H38Cl2N4O12Zn·2H2O理论值C,44.00;H,5.17;N,6.84.实验值:C,43.83;H,5.41;N,6.57%.1H-NMR(ppm,DMSO--d6):8.33(s,2H),7.09(d,2H),6.19(d,2H),6.12(m,2H),4.41(s,4H),3.76(t,4H),3.66(s,4H),3.17(s,18H).
实施例4
(1)同实施例1;
(2)Salen Zn(II)配合物4的合成:
称取高氯酸季胺盐170mg(0.5mmol)置于50mL三颈烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。在氩气保护下向该溶液中加入27mg(0.25mmol)2,3-二胺吡啶,加热回流2h,溶液变成棕黄色。然后加入二水合醋酸锌110mg(0.5mmol)的甲醇溶液,加热回流3h后停止加热,将溶液放入冰箱冷却,得到黄绿色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到黄绿色粉末固体163mg。产率80%。
元素分析C29H37Cl2N5O12Zn·2H2O理论值:C,42.48;H,5.04;N,8.54.实验值:C,42.16;H,5.32;N,8.36%.1H-NMR(ppm,DMSO--d6):9.35(s,1H),8.98(s,1H),8.32(d,1H),8.25(d,1H),7.42(d,1H),7.36(m,2H),6.31(s,2H),6.25(m,2H),4.48(s,4H),3.80(s,4H),3.19(s,18H).
实施例5
(1)同实施例1;
(2)Salen Zn(II)配合物5的合成:
称取高氯酸季胺盐170mg(0.5mmol)置于50mL圆底烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。向该溶液中加入27mg(0.25mmol)3,4-二胺吡啶,加热回流2h,溶液变成黄色。然后加入二水合醋酸锌220mg(1mmol)的甲醇溶液,加热回流3h后停止加热,将溶液放入冰箱冷却,得到橙黄色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到橙黄色粉末固体177mg。产率86%。
元素分析C29H37Cl2N5O12Zn·2H2O理论值:C,42.48;H,5.04;N,8.54.实验值:C,42.20;H,5.28;N,8.28%.1H-NMR(ppm,DMSO--d6):9.04(t,3H),8.43(d,1H),7.77(d,1H),7.36(t,2H),6.29(d,2H),6.26(t,2H),4.48(d,4H),3.79(s,4H),3.19(s,18H).
实施例6
(1)同实施例1;
(2)Salen Zn(II)配合物6的合成:
称取高氯酸季胺盐170mg(0.5mmol)置于50mL三颈烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。在氩气的保护下,向该溶液中加入34mg(0.25mmol)4-甲氧基邻苯二胺,加热回流2h后加入二水合醋酸锌110mg(0.5mmol)的甲醇溶液,加热回流3h后停止加热,将溶液放入冰箱冷却,得到绿色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到绿色粉末固体120mg。产率56%。
元素分析C31H40Cl2N4O13Zn·2H2O实验值:C,43.85;H,5.22;N,6.60.理论值:C,43.59;H,5.48;N,6.34%.1H-NMR(ppm,DMSO--d6):8.92(s,1H),8.83(s,1H),7.77(d,1H),7.38(t,2H),7.32(d,1H),6.92(d,1H),6.24(m,4H),4.49(s,4H),3.87(s,3H),3.79(t,4H),3.19(s,18H).
实施例7
(1)同实施例1;
(2)Salen Zn(II)配合物7的合成:
称取高氯酸季胺盐170mg(0.5mmol)置于50mL圆底烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。向该溶液中加入30mg(0.25mmol)3,4-二氨基甲苯,加热回流2h,溶液变成棕黄色。然后加入二水合醋酸锌110mg(0.5mmol)的甲醇溶液,加热回流3h后停止加热,将溶液放入冰箱冷却,得到黄色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到黄色粉末固体170mg。产率82%。
元素分析C31H40Cl2N4O12Zn·2H2O理论值:C,44.70;H,5.32;N,6.73.实验值:C,44.47;H,5.53;N,6.57%.1H-NMR(ppm,DMSO--d6):8.88(d,2H),7.71(d,1H),7.65(s,1H),7.34(t,2H),7.14(d,1H),6.27(s,2H),6.23(t,2H),4.46(s,4H),3.79(s,4H),3.19(s,18H),2.39(s,3H).
实施例8
(1)同实施例1;
(2)Salen Zn(II)配合物8的合成:
称取高氯酸季胺盐170mg(0.5mmol)置于50mL圆底烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。向该溶液中加入31mg(0.25mmol)4-氟邻苯二胺,加热回流2h,溶液变成棕褐色。然后加入二水合醋酸锌110mg(0.5mmol)的甲醇溶液,加热回流3h后停止加热,将溶液放入冰箱冷却,得到黄绿色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到黄绿色粉末固体180mg。产率86%。
元素分析C30H37Cl2FN4O12Zn·2H2O理论值:C,43.05;H,4.94;N,6.69.实验值:C,42.91;H,4.70;N,6.43%.1H-NMR(ppm,DMSO--d6):8.90(d,2H),7.86(q,1H),7.74(d,1H),7.34(q,2H),7.16(t,1H),6.28(s,2H),6.24(t,2H),4.47(s,4H),3.79(s,4H),3.19(s,18H).
实施例9
(1)同实施例1;
(2)Salen Zn(II)配合物9的合成:
称取高氯酸季胺盐170mg(0.5mmol)置于50mL圆底烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。向该溶液中加入38mg(0.25mmol)4-硝基邻苯二胺,加热回流2h,溶液变成黄色。然后加入二水合醋酸锌110mg(0.5mmol)的甲醇溶液,加热回流3h后停止加热,将溶液放入冰箱冷却,得到橙黄色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到橙黄色粉末固体190mg。产率88%。
元素分析C31H40Cl2N4O13Zn·2H2O理论值:C,43.85;H,5.22;N,6.60.实验值:C,43.59;H,5.48;N,6.34%.1H-NMR(ppm,DMSO--d6):9.09(s,IH),9.03(s,1H),8.68(d,1H),8.15(q,1H),8.03(d,1H),7.47(d,1H),7.39(d,1H),6.28(m,4H),4.49(s,4H),3.80(t,4H),3.19(s,18H).
实施例10
(1)同实施例1;
(2)Salen Zn(II)配合物10的合成:
称取高氯酸季胺盐170mg(0.5mmol)置于50mL圆底烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。向该溶液中加入53mg(0.25mmol)3,4-二氨基二苯甲酮,加热回流2h,溶液变成黄色。然后加入二水合醋酸锌110mg(0.5mmol)的甲醇溶液,加热回流3h后停止加热,将溶液放入冰箱冷却,得到黄色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到橙黄色粉末固体202mg。产率88%。
元素分析C37H42Cl2N4O13Zn·2H2O理论值:C,48.14;H,5.02;N,6.07.实验值:C,47.94;H,5.29;N,5.82%.1H-NMR(ppm,DMSO--d6):8.93(s,1H),8.40(S,1H),8.32(d,1H),8.21(m,3H),8.16(s,1H),8.11(m,2H),7.92(q,4H),7.81(t,2H),7.48(d,1H),7.34(d,1H),7.12(d,1H),6.79(d,1H),6.26(s,3H),4.45(d,4H),3.79(m,4H),3.19(s,18H),1.85(s,4H).
实施例11
(1)同实施例1;
(2)Salen Zn(II)配合物11的合成:
称取高氯酸季胺盐170mg(0.5mmol)置于50mL圆底烧瓶中,加入15mL无水甲醇,缓慢加热至高氯酸季胺盐全部溶解,得到无色透明溶液。向该溶液中加入39mg(0.25mmol)2,3-二氨基萘加热回流2h,溶液变成橙色。然后加入二水合醋酸锌110mg(0.5mmol)的甲醇溶液,加热回流3h后停止加热,将溶液放入冰箱冷却,得到黄色沉淀,用冷甲醇5mL洗两次,真空干燥后称重得到橙黄色粉末固体208mg。产率95%。
元素分析C34H40Cl2N4O12Zn·2H2O理论值:C,46.99;H,5.10;N,6.45.实验值:C,46.62;H,5.36;N,6.19%.1H-NMR(ppm,DMSO--d6):9.05(S,2H),8.24(S,2H),7.48(q,2H),7.40(d,2H),6.30(d,2H),6.26(d,1H),6.25(d,1H),4.49(s,4H),3.80(t,4H),3.19(s,18H),1.79(s,2H).
实施例12
化合物性质测定:
1.Salen Zn(II)与RNA结合实验的UV-Vis滴定法测定:
Salen Zn(II)和RNA溶液的配置均采用称量法。更加精确的浓度采用各自的摩尔消光系数测定。溶剂为二次蒸馏水,缓冲体系为Tris-NaCl,pH 7.0。主体Salen Zn配合物的浓度为2×10-5mol/L,客体浓度范围约为5×10-6~5×10-5mol/L,向固定浓度的Salen金属配合物的溶液中逐渐增加RNA的浓度,分别记录配合物本身和不同RNA浓度下的紫外可见光谱,根据曲线拟合计算推测配合物与poly A以及tRNA的结合方式和作用强度。
以配合物6为例,从紫外滴定图中可以看到,随着客体浓度的增加,367nm处吸光度逐渐降低,而467nm处吸光度逐渐升高,各条吸光曲线清晰地交于一点。吸收曲线的变化反应了主体不断消耗和产物不断形成的过程。配合物利用轴向配位能力与RNA结构中单链部位碱基中的电子给体形成配位键,与仅靠静电作用、疏水作用、氢键以及π-π堆积等弱相互作用相比,具有更高亲和力的RNA结合试剂,从而有利于阻断逆转录酶对病毒RNA的逆转录作用。
2.系列Salen Zn(II)配合物体外逆转录酶抑制实验
对合成的一系列Salen Zn(II)配合物,采用凝胶电泳法测试其抑制逆转录酶的作用:
利用莫洛尼氏鼠类白血病毒(M-MLV)逆转录酶,在标准条件下,将模板RNA逆转录成相应的cDNA。通过比较在存在和不存在Salen金属配合物的条件下cDNA的生成能力的差别,定量的确定配合物抑制半数逆转录酶活性的浓度(IC50),从而比较不同结构的Salen金属配合物抑制逆转录酶的能力。
操作流程:
配制每份20μL对照组溶液与反应液,每份反应组溶液中含有模板RNA为1μg,引物1μg,M-MuLV RT 1μg,不同浓度的Salen Zn(II)配合物。对照组1为模板RNA,即poly A,对照组2为不加配合物的反应组溶液。37℃下温浴1h后,加入溴酚蓝上样缓冲液终止反应。上样至2wt%的琼脂糖凝胶板,在TBE中以80V电泳1h。以1μg/mL的EB染色液染色30min。用Alpha Innotech IS-5500化学荧光成像分析系统记录电泳图片。
结果表明,配合物1~11均能在5~50μM浓度范围内抑制半数逆转录酶活性,表现出较高的抑制活性。
Claims (9)
2.根据权利要求1所述的Salen Zn(II)配合物,其特征在于所述为乙二胺、环己二胺、二氨基马来腈、苯二胺、2,3-二胺基吡啶、3,4-二胺基吡啶、4-甲氧基邻苯二胺、3,4-二氨基甲苯、4-氟邻苯二胺、4-硝基邻苯二胺、3,4-二氨基二苯甲酮或2,3-二氨基萘。
3.根据权利要求2所述的Salen Zn(II)配合物,其特征在于所述阴离子部分为高氯酸根。
4.权利要求1或2或3所述Salen Zn(II)配合物的制备方法,其特征在于包括如下步骤:将高氯酸季铵盐与二胺混合,加热回流2h后,向反应液中加入金属盐,继续回流2~3h,停止加热,冷却后析出大量沉淀,经抽滤得到Salen Zn(II)配合物。
5.根据权利要求4所述Salen Zn(II)配合物的制备方法,其特征在于所述高氯酸季铵盐、二胺和金属盐的摩尔比为2∶1∶2。
6.根据权利要求4所述Salen Zn(II)配合物的制备方法,其特征在于所述二胺为乙二胺,环己二胺,二氨基马来腈,苯二胺,2,3-二胺基吡啶,3,4-二胺基吡啶,4-甲氧基邻苯二胺,3,4-二氨基甲苯,4-氟邻苯二胺,4-硝基邻苯二胺,3,4-二氨基二苯甲酮,2,3-二氨基萘。
7.根据权利要求4所述Salen Zn(II)配合物的制备方法,其特征在于所述金属盐为醋酸锌。
8.根据权利要求4所述Salen Zn(II)配合物的制备方法,其特征在于当合成含有2,3-二胺基吡啶或4-甲氧基邻苯二胺的alen Zn(II)配合物时,需要在氩气的保护下进行。
9.权利要求1或2或3所述Salen Zn(II)配合物在制备RNA结合试剂或RNA逆转录酶抑制剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010132979.XA CN101830828B (zh) | 2010-03-23 | 2010-03-23 | 一种Salen Zn(II)配合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010132979.XA CN101830828B (zh) | 2010-03-23 | 2010-03-23 | 一种Salen Zn(II)配合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101830828A true CN101830828A (zh) | 2010-09-15 |
CN101830828B CN101830828B (zh) | 2014-06-25 |
Family
ID=42715068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010132979.XA Expired - Fee Related CN101830828B (zh) | 2010-03-23 | 2010-03-23 | 一种Salen Zn(II)配合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101830828B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102199286A (zh) * | 2011-04-08 | 2011-09-28 | 南京航空航天大学 | 基于聚Salen配体的、不同锌(Ⅱ)、铂(Ⅱ)掺杂比例的金属配合物及其制备方法、应用 |
CN102304062A (zh) * | 2011-06-09 | 2012-01-04 | 山东省化工研究院 | 一种Salen Ni的制备方法 |
CN102617369A (zh) * | 2012-02-17 | 2012-08-01 | 华东理工大学 | 类salan单酚类配体金属络合物及其制备方法与应用 |
CN104649930A (zh) * | 2015-02-11 | 2015-05-27 | 桂林理工大学 | 具抗癌活性的配合物[Zn(H2L4)2].(H2O)的合成及应用 |
CN109096339A (zh) * | 2018-07-20 | 2018-12-28 | 云南大学 | 一种三联吡啶钌配合物的制备及在逆转录酶抑制中的应用 |
CN110467633A (zh) * | 2018-05-11 | 2019-11-19 | 北京大学 | 主族金属配合物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1737002A (zh) * | 2005-07-29 | 2006-02-22 | 南开大学 | 季胺基团修饰水溶性手性席夫碱金属配合物及其合成方法 |
-
2010
- 2010-03-23 CN CN201010132979.XA patent/CN101830828B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1737002A (zh) * | 2005-07-29 | 2006-02-22 | 南开大学 | 季胺基团修饰水溶性手性席夫碱金属配合物及其合成方法 |
Non-Patent Citations (4)
Title |
---|
刘阁等: "新型水溶性手性Salen配合物的合成及性质研究", 《化学学报》 * |
史秀丽等: "季胺基修饰的Salen配合物的合成及性质", 《化学学报》 * |
朱必学等: "双核Salen 锌配合物对含氮小分子的分子识别研究", 《高等学校化学学报》 * |
高峰等: "含吡唑三齿配体的锌配合物的合成和晶体结构", 《徐州师范大学学报》 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102199286A (zh) * | 2011-04-08 | 2011-09-28 | 南京航空航天大学 | 基于聚Salen配体的、不同锌(Ⅱ)、铂(Ⅱ)掺杂比例的金属配合物及其制备方法、应用 |
CN102199286B (zh) * | 2011-04-08 | 2012-12-12 | 南京航空航天大学 | 基于聚Salen配体的、不同锌(Ⅱ)、铂(Ⅱ)掺杂比例的金属配合物及其制备方法、应用 |
CN102304062A (zh) * | 2011-06-09 | 2012-01-04 | 山东省化工研究院 | 一种Salen Ni的制备方法 |
CN102304062B (zh) * | 2011-06-09 | 2013-11-06 | 山东省化工研究院 | 一种Salen Ni的制备方法 |
CN102617369A (zh) * | 2012-02-17 | 2012-08-01 | 华东理工大学 | 类salan单酚类配体金属络合物及其制备方法与应用 |
CN102617369B (zh) * | 2012-02-17 | 2014-10-15 | 华东理工大学 | 类salan单酚类配体金属络合物及其制备方法与应用 |
CN104649930A (zh) * | 2015-02-11 | 2015-05-27 | 桂林理工大学 | 具抗癌活性的配合物[Zn(H2L4)2].(H2O)的合成及应用 |
CN110467633A (zh) * | 2018-05-11 | 2019-11-19 | 北京大学 | 主族金属配合物及其制备方法和应用 |
CN109096339A (zh) * | 2018-07-20 | 2018-12-28 | 云南大学 | 一种三联吡啶钌配合物的制备及在逆转录酶抑制中的应用 |
CN109096339B (zh) * | 2018-07-20 | 2020-10-02 | 云南大学 | 一种三联吡啶钌配合物的制备及在逆转录酶抑制中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101830828B (zh) | 2014-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abdel-Rahman et al. | DNA interaction, antimicrobial, anticancer activities and molecular docking study of some new VO (II), Cr (III), Mn (II) and Ni (II) mononuclear chelates encompassing quaridentate imine ligand | |
Abdel-Rahman et al. | Design and nonlinear optical properties (NLO) using DFT approach of new Cr (III), VO (II), and Ni (II) chelates incorporating tri-dentate imine ligand for DNA interaction, antimicrobial, anticancer activities and molecular docking studies | |
Prabhakaran et al. | Synthesis, DNA/protein binding and in vitro cytotoxic studies of new palladium metallothiosemicarbazones | |
Li et al. | Synthesis, characterization and biological activity of lanthanum (III) complexes containing 2-methylene–1, 10-phenanthroline units bridged by aliphatic diamines | |
Wu et al. | V-shaped ligand bis (2-benzimidazolylmethyl) amine containing three copper (II) ternary complexes: Synthesis, structure, DNA-binding properties and antioxidant activity | |
CN101830828B (zh) | 一种Salen Zn(II)配合物及其制备方法和应用 | |
Kemp et al. | The effect of ancillary ligand chirality and phenanthroline functional group substitution on the cytotoxicity of platinum (II)-based metallointercalators | |
CN102268046B (zh) | 基于9-咪蒽腙的类顺铂型配合物及其合成方法和应用 | |
Sumrra et al. | Computational investigation of molecular structures, spectroscopic properties, cholinesterase inhibition and antibacterial activities of triazole Schiff bases endowed metal chelates | |
Thamilarasan et al. | Cobalt (III) complexes as potential anticancer agents: Physicochemical, structural, cytotoxic activity and DNA/protein interactions | |
Ali et al. | Copper (II) complexes of substituted salicylaldehyde dibenzyl semicarbazones: synthesis, cytotoxicity and interaction with quadruplex DNA | |
Ayyannan et al. | Design, synthesis, structure and biological evaluation of new palladium (II) hydrazone complexes | |
Alagesan et al. | An investigation on new ruthenium (II) hydrazone complexes as anticancer agents and their interaction with biomolecules | |
Chanda et al. | Effect of 2-(2-Pyridyl) azole-Based Ancillary Ligands (L1-4) on the Electrophilicity of the Nitrosyl Function in [RuII (trpy)(L1-4)(NO)] 3+[trpy= 2, 2 ‘: 6 ‘, 2 ‘‘-Terpyridine]. Synthesis, Structures, and Spectroscopic, Electrochemical, and Kinetic Aspects | |
El-Medani et al. | Spectroscopic, crystal structural, theoretical and biological studies of phenylacetohydrazide Schiff base derivatives and their copper complexes | |
Kongot et al. | In vitro apoptosis-induction, antiproliferative and BSA binding studies of a oxidovanadium (V) complex | |
Jia et al. | Synthesis, crystal structure, DNA-binding properties, cytotoxic and antioxidation activities of several ternary copper (II) complexes with a new reduced Schiff base ligand | |
Shanmugapriya et al. | CT-DNA/BSA protein binding and antioxidant studies of new binuclear Pd (II) complexes and their structural characterisation | |
Navarro et al. | Synthesis and characterization of new palladium–clotrimazole and palladium–chloroquine complexes showing cytotoxicity for tumor cell lines in vitro | |
Ayyannan et al. | New palladium (II) hydrazone complexes: Synthesis, structure and biological evaluation | |
Ghosh et al. | Reactivity of nitric oxide with ruthenium complexes derived from bidentate ligands: structure of a ruthenium nitrosyl complex, photoinduced generation and estimation of nitric oxide | |
Kumar et al. | Synthesis, structural analysis and cytotoxic effect of copper (II)-thiosemicarbazone complexes having heterocyclic bases: A selective naked eye sensor for F− and CN− | |
Kalaivani et al. | Photophysical properties and in vitro cytotoxicity studies of new Ru (II) carbonyl complexes and mixed geometrical Ru (II)–Ni (II) complex in HS-DNA/BSA protein and human lung (A549) and liver (HepG2) cells | |
Liu et al. | 2-(3, 5-Dibromo-4-hydroxyphenyl) imidazo [4, 5-f][1, 10] phenanthrolinoruthenium (II) complexes: synthesis, characterization, cytotoxicity, apoptosis, DNA-binding and antioxidant activity | |
Mohammadlou et al. | A new zinc (II) complex of 2-benzoimidazoledisulfide ligand: synthesis, X-ray crystallographic structure, investigation of CT-DNA and BSA interaction by spectroscopic techniques and molecular docking |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140625 Termination date: 20160323 |
|
CF01 | Termination of patent right due to non-payment of annual fee |